Literature DB >> 27021495

Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: questionnaire survey in Japan over a 1-year period.

Ryutaro Tanizaki1, Mugen Ujiie2, Narumi Hori1, Shuzo Kanagawa1, Satoshi Kutsuna1, Nozomi Takeshita1, Kayoko Hayakawa1, Yasuyuki Kato1, Norio Ohmagari1.   

Abstract

BACKGROUND: A live attenuated yellow fever (YF) vaccination is required of all travellers visiting countries where YF virus is endemic. Although the risk of serious adverse events (AEs) after YF vaccination is known to be greater in elderly people than in younger people, information about other AEs among elderly travellers is lacking.
METHODS: A prospective observational questionnaire study was conducted to investigate the occurrence of AEs after YF vaccination in travellers who attended a designated YF vaccination centre in Tokyo, Japan, from 1 November 2011 to 31 October 2012. A questionnaire enquiring about any AEs experienced in the 2 weeks following YF vaccination was distributed to all vaccinees enrolled in this study, and responses were collected subsequently by mail or phone. For child vaccinees, their parents were allowed to respond in their stead.
RESULTS: Of the 1298 vaccinees who received the YF vaccine, 1044 (80.4%) were enrolled in the present study and 666 (63.8%) responded to the questionnaire. Of these 666 respondents, 370 (55.6%) reported AEs, of which 258 (38.7%) were systemic and 230 (34.5%) were local. No severe AEs associated with YF vaccination were reported. Elderly vaccinees (aged ≥60 years) reported fewer total AEs than those aged <60 years (42.9% vs 60.3%;P < 0.001).
CONCLUSION: Our study showed that fewer general AEs after yellow vaccination reported among elderly vaccinees than among non-elderly vaccinees. These results could provide supplementary information for judging the adaptation of vaccination in elderly travellers. © International Society of Travel Medicine, 2016. All rights reserved. Published by Oxford University Press. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Yellow fever; adverse event; elderly; questionnaire; traveller; vaccination

Mesh:

Substances:

Year:  2016        PMID: 27021495     DOI: 10.1093/jtm/taw012

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


  6 in total

Review 1.  A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population.

Authors:  Ariane de Jesus Lopes de Abreu; João Roberto Cavalcante; Letícia Wigg de Araújo Lagos; Rosângela Caetano; José Ueleres Braga
Journal:  Vaccines (Basel)       Date:  2022-04-30

Review 2.  Yellow Fever in Travelers.

Authors:  Annelies Wilder-Smith
Journal:  Curr Infect Dis Rep       Date:  2019-10-31       Impact factor: 3.725

Review 3.  Yellow fever vaccine and risk of developing serious adverse events: a systematic review.

Authors:  Ruben Porudominsky; Eduardo H Gotuzzo
Journal:  Rev Panam Salud Publica       Date:  2018-06-05

4.  Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis.

Authors:  Itay Lotan; Mark A Hellmann; Yitzhak Friedman; Hadas Stiebel-Kalish; Israel Steiner; Adi Wilf-Yarkoni
Journal:  Neuromuscul Disord       Date:  2022-02-05       Impact factor: 4.296

5.  Screening test for neutralizing antibodies against yellow fever virus, based on a flavivirus pseudotype.

Authors:  Séverine Mercier-Delarue; Christine Durier; Nathalie Colin de Verdière; Jean-Dominique Poveda; Vincent Meiffrédy; Maria Dolores Fernandez Garcia; Stéphane Lastère; Raymond Césaire; Jean-Claude Manuggera; Jean-Michel Molina; Ali Amara; François Simon
Journal:  PLoS One       Date:  2017-05-31       Impact factor: 3.240

6.  Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel.

Authors:  Itay Lotan; Adi Wilf-Yarkoni; Yitzhak Friedman; Hadas Stiebel-Kalish; Israel Steiner; Mark A Hellmann
Journal:  Eur J Neurol       Date:  2021-08-02       Impact factor: 6.288

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.